About the Speaker 

Marc Johnson, PhD researches retroviral assembly, a biological process involving multiple viral and cellular actors from diverse locations within the cell. These actors converge at defined assembly sites to create and facilitate the egress of an infectious viral particle. Dr. Johnson utilizes the model retrovirus HIV‐1 to study the basic viral components targeted to viral assembly sites, including how cellular processes are usurped to aid in this process. Dr. Johnson’s lab is studying how viruses target their cytoplasmic structural proteins to the same assembly sites as their trans‐ membrane targeting/fusion glycoproteins. Research has led to the theory that viruses utilize a common glycoprotein targeting pathway/mechanism to drive viral incorporation. A better understanding of this process could lead to novel therapeutics against viruses as well as enhanced ability to custom design viruses for use in precision medicine applications. Additionally, Dr. Johnson’s lab studies the HIV-1 accessory protein Vpu. Inhibitors of Vpu activity could be an important component of therapies aimed at eliminating reservoirs of HIV infected cells (cure). Dr. Johnson’s lab has found that Vpu targets the viral glycoprotein from Gibbon ape Leukemia Virus (GaLV Env) and prevents it from being incorporated into HIV-1 viral particles. Dr. Johnson is currently developing several small molecules with anti-Vpu activity as potential therapeutics for HIV-1 infected patients.

For more information:

please visit the event page on the NextGen Precision Health website.

The NextGen Precision Health Discovery Series provides learning opportunities for UM System faculty and staff across disciplines, the statewide community and our other partners to learn about the scope of precision health research and identify potential collaborative opportunities.

For questions about this event or any others in the Discovery Series, please reach out to Mary Christie at mchristie@health.missouri.edu